PL2463368T3 - Humanizowane przeciwciało anty-oligomer amyloidu B - Google Patents
Humanizowane przeciwciało anty-oligomer amyloidu BInfo
- Publication number
- PL2463368T3 PL2463368T3 PL10806566T PL10806566T PL2463368T3 PL 2463368 T3 PL2463368 T3 PL 2463368T3 PL 10806566 T PL10806566 T PL 10806566T PL 10806566 T PL10806566 T PL 10806566T PL 2463368 T3 PL2463368 T3 PL 2463368T3
- Authority
- PL
- Poland
- Prior art keywords
- amyloid
- humanized anti
- oligomer antibody
- oligomer
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23203809P | 2009-08-07 | 2009-08-07 | |
| PCT/JP2010/063430 WO2011016567A1 (ja) | 2009-08-07 | 2010-08-06 | 抗アミロイドβオリゴマーヒト化抗体 |
| EP10806566.5A EP2463368B1 (en) | 2009-08-07 | 2010-08-06 | Humanized anti-amyloid-b oligomer antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2463368T3 true PL2463368T3 (pl) | 2018-07-31 |
Family
ID=43544461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10806566T PL2463368T3 (pl) | 2009-08-07 | 2010-08-06 | Humanizowane przeciwciało anty-oligomer amyloidu B |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8333967B2 (pl) |
| EP (1) | EP2463368B1 (pl) |
| JP (1) | JP5051806B2 (pl) |
| KR (1) | KR101787118B1 (pl) |
| CN (1) | CN102597234B (pl) |
| AU (1) | AU2010279892B8 (pl) |
| BR (1) | BR112012002819B1 (pl) |
| CA (1) | CA2769464C (pl) |
| DK (1) | DK2463368T3 (pl) |
| ES (1) | ES2661601T3 (pl) |
| HU (1) | HUE036392T2 (pl) |
| MX (1) | MX2012001708A (pl) |
| PL (1) | PL2463368T3 (pl) |
| PT (1) | PT2463368T (pl) |
| SG (1) | SG177679A1 (pl) |
| WO (1) | WO2011016567A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015159963A1 (ja) * | 2014-04-16 | 2015-10-22 | 協和発酵キリン株式会社 | ヒトｃｓｆの毒性を測定する方法 |
| CN108431037B (zh) * | 2016-01-12 | 2021-12-17 | 国立大学法人千叶大学 | 抗myl9抗体 |
| CN107118260B (zh) * | 2017-05-12 | 2020-10-16 | 中国科学院过程工程研究所 | 一种多肽及其组成的疫苗和应用 |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| US12016885B2 (en) * | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN117586388A (zh) * | 2022-08-09 | 2024-02-23 | 深圳智源生物医药有限公司 | 改进的β淀粉样蛋白寡聚体特异性结合抗体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| AU690474B2 (en) | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US20050059591A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| CA2544692C (en) * | 2004-07-09 | 2014-04-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| JP3806883B2 (ja) | 2004-09-28 | 2006-08-09 | ダイキン工業株式会社 | 空気調和装置 |
| CA2790433A1 (en) * | 2004-10-25 | 2006-05-26 | Northwestern University | Anti-addl antibodies and uses thereof |
| AU2005306997B2 (en) * | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
| US8716451B2 (en) | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| EP2210901A4 (en) * | 2007-10-19 | 2012-04-25 | Immunas Pharma Inc | FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE |
| EP2246427B1 (en) * | 2008-02-08 | 2016-11-30 | Immunas Pharma, Inc. | Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof |
| WO2011155607A1 (ja) * | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
-
2010
- 2010-08-06 MX MX2012001708A patent/MX2012001708A/es active IP Right Grant
- 2010-08-06 HU HUE10806566A patent/HUE036392T2/hu unknown
- 2010-08-06 KR KR1020127003173A patent/KR101787118B1/ko active Active
- 2010-08-06 ES ES10806566.5T patent/ES2661601T3/es active Active
- 2010-08-06 SG SG2012003208A patent/SG177679A1/en unknown
- 2010-08-06 AU AU2010279892A patent/AU2010279892B8/en active Active
- 2010-08-06 CN CN201080035051.8A patent/CN102597234B/zh active Active
- 2010-08-06 DK DK10806566.5T patent/DK2463368T3/en active
- 2010-08-06 EP EP10806566.5A patent/EP2463368B1/en active Active
- 2010-08-06 WO PCT/JP2010/063430 patent/WO2011016567A1/ja not_active Ceased
- 2010-08-06 JP JP2011525961A patent/JP5051806B2/ja active Active
- 2010-08-06 PT PT108065665T patent/PT2463368T/pt unknown
- 2010-08-06 CA CA2769464A patent/CA2769464C/en active Active
- 2010-08-06 PL PL10806566T patent/PL2463368T3/pl unknown
- 2010-08-06 BR BR112012002819-7A patent/BR112012002819B1/pt active IP Right Grant
- 2010-08-09 US US12/852,548 patent/US8333967B2/en active Active
-
2012
- 2012-11-15 US US13/678,214 patent/US9181332B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010279892A8 (en) | 2014-09-25 |
| AU2010279892B8 (en) | 2014-09-25 |
| US20120009179A1 (en) | 2012-01-12 |
| JP5051806B2 (ja) | 2012-10-17 |
| EP2463368A9 (en) | 2012-11-28 |
| PT2463368T (pt) | 2018-02-08 |
| BR112012002819A2 (pt) | 2017-07-11 |
| KR101787118B1 (ko) | 2017-10-18 |
| ES2661601T3 (es) | 2018-04-02 |
| EP2463368B1 (en) | 2018-01-10 |
| MX2012001708A (es) | 2012-05-22 |
| BR112012002819B1 (pt) | 2022-11-22 |
| CA2769464C (en) | 2017-11-21 |
| EP2463368A1 (en) | 2012-06-13 |
| KR20120038474A (ko) | 2012-04-23 |
| US20130095526A1 (en) | 2013-04-18 |
| AU2010279892B2 (en) | 2014-05-22 |
| RU2012108610A (ru) | 2013-09-20 |
| CN102597234A (zh) | 2012-07-18 |
| SG177679A1 (en) | 2012-02-28 |
| WO2011016567A1 (ja) | 2011-02-10 |
| EP2463368A4 (en) | 2013-09-18 |
| CA2769464A1 (en) | 2011-02-10 |
| AU2010279892A1 (en) | 2012-02-09 |
| US8333967B2 (en) | 2012-12-18 |
| HUE036392T2 (hu) | 2018-07-30 |
| US9181332B2 (en) | 2015-11-10 |
| CN102597234B (zh) | 2014-10-29 |
| JPWO2011016567A1 (ja) | 2013-01-17 |
| DK2463368T3 (en) | 2018-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217919A0 (en) | Humanized anti-cdcp1 antibodies | |
| SG10201401331TA (en) | Anti-siglec-15 antibody | |
| ZA201106480B (en) | Humanized anti-cd19 antibody formulations | |
| IL220404A (en) | Antiseptic antibodies | |
| IL214996A0 (en) | Anti-bcma antibodies | |
| GB0920127D0 (en) | Antibodies | |
| GB0909906D0 (en) | Antibodies | |
| PL2581113T3 (pl) | Przeciwciało anty-tim-3 | |
| PT3342786T (pt) | Anticorpo anti-dll3 | |
| PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
| EP2463369A4 (en) | HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS | |
| EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
| ZA201202227B (en) | Monoclonal antibodies | |
| PL2636736T3 (pl) | Nowe przeciwciało anty-dr5 | |
| PT2463368T (pt) | Anticorpo humanizado anti oligómero de amilóide b | |
| GB0920324D0 (en) | Antibodies | |
| GB0905972D0 (en) | Antibodies against IL-17BR | |
| EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
| GB2473934B (en) | Anti-VEEV antibody | |
| GB201007957D0 (en) | Antibody | |
| GB0911712D0 (en) | Antibody | |
| GB0804686D0 (en) | Humanized antibody | |
| GB0804687D0 (en) | Humanized antibody | |
| GB0804684D0 (en) | Humanized antibody | |
| GB0908945D0 (en) | Antibodies |